Bastiaan Sallevelt

89 Evaluation of clarity of the STOPP/START criteria - SI Table SI1.1. Continued. STOPP Action Clarity rating Condition Clarity rating Explanation Clarity rating I I1 Antimuscarinic drugs 17% with dementia, or chronic cognitive impairment or narrow-angle glaucoma or chronic prostatism 42% (risk of increased confusion, agitation / risk of urinary retention). 67% I2 Selective alpha-1 selective alpha blockers 67% in those with symptomatic orthostatic hypotension or micturition syncope 50% (risk of precipitating recurrent syncope). 75% J J1 Sulphonylureas with a long duration of action (e.g. glibenclamide, chlorpropamide, glimepiride) 50% with type 2 diabetes mellitus 75% (risk of prolonged hypoglycaemia). 75% J2 Thiazolidenediones (e.g. rosiglitazone, pioglitazone) 50% in patients with heart failure 58% (risk of exacerbation of heart failure). 67% J3 Beta-blockers 67% in diabetes mellitus with frequent hypoglycaemic episodes 50% (risk of suppressing hypoglycaemic symptoms). 83% J4 Oestrogens 67% with a history of breast cancer or venous thromboembolism 83% (increased risk of recurrence). 67% J5 Oral oestrogens 83% without progestogen in patients with intact uterus 100% (risk of endometrial cancer). 67% 2